AMX0035

Unassigned

New Medicines

Amyotrophic lateral sclerosis (motor neurone disease)

Information

New molecular entity
Amylyx
Amylyx

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Targets endoplasmic reticulum and mitochondrial dependent neuronal degeneration pathways
Amyotrophic lateral sclerosis motor neurone disease (ALS MND) is uncommon, estimated to affect 4000 people in the UK [1].
Amyotrophic lateral sclerosis (motor neurone disease)
Oral